urokinase-type plasminogen activator


Also found in: Dictionary, Thesaurus, Encyclopedia.
Related to urokinase-type plasminogen activator: Plasminogen activator inhibitor

Abbokinase

A proprietary formulation of urokinase, a thrombolytic that activates the fibrinolysis by increasing plasmin production from plasminogen, thereby degrading fibrin clots, fibrinogen, and other clotting factors.

urokinase-type plasminogen activator

Abbreviation: uPA
A protein that degrades extracellular tissues. It has been linked to the spread of some cancers by invasion and metastasis.
See also: activator
References in periodicals archive ?
Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.
suPAR: soluble urokinase-type plasminogen activator receptor; IL-6: interleukin-6; CRP: c-reactive protein; CI: confidence interval.
Yonemura et al., "Association of immunohistochemical detection of urokinase-type plasminogen activator with metastasis and prognosis in colorectal cancer," Oncology, vol.
Kapoor et al., "A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease," Kidney International, vol.
Matucci Cerinic, "The urokinase-type plasminogen activator system and inflammatory joint diseases," Clinical and Experimental Rheumatology, vol.
Soluble urokinase-type plasminogen activator receptor (suPAR) as an independent factor predicting worse prognosis and extra-bone marrow involvement in multiple myeloma patients.
Induction of urokinase-type plasminogen activator by the anthracycline antibiotic in human RC-K8 lymphoma and H69 lung-carcinoma cells.
ViroGates A/S (Birkerod, Denmark) has patented a method of diagnosing and/or prognosticating HIV infection in a subject comprising the steps of: (a) performing in vitro a measurement of the level of a marker in the form of (i) urokinase plasminogen activator receptor (uPAR), (ii) soluble urokinase plasminogen activator receptor (suPAR), (iii) urokinase-type plasminogen activator (uPA), (iv) one or more degradation products of (i), (ii) or (iii), and/or (v) an mRNA for (i), (ii) or (iii), in a biological fluid sample from a subject, and (b) using the measurement value obtained to evaluate the state of the subject.
Relation of serum vascular endothelial growth factor as an angiogenesis biomarker with nitric oxide and urokinase-type plasminogen activator in breast cancer patients.
Specifically, the researchers have examined the effects of alcohol and polyphenols on the expression of proteins and pathways that can lead to increased fibrinolysis (including, tissue-type plasminogen activator, t-PA; urokinase-type plasminogen activator, u-PA and plasminogen activator inhibitor type 1, PAI-1).
The researchers studied urokinase-type plasminogen activator (uPA) and its inhibitor, called PAI-1, proteins that are involved in cell migration within the body.
Several biomarkers look promising, but the combination of urokinase-type plasminogen activator (uPA) and plasma activation inhibitor-1 (PAI-1) is actually ready for prime time use in clinical practice, Dr.